Cleveland Diagnostics

Cleveland Diagnostics

Private
Cleveland, OhioHealthcare & Life Scienceshttps://clevelanddx.com

Last Round

VC Round

Jan 17, 2024

Est. Valuation

$13.2M

Total Funding Raised

$23.38M

Momentum Score

25 /100

Company Overview

Cleveland Diagnostics is a biotechnology company that develops non-invasive diagnostic tests for early cancer detection using a proprietary platform that analyzes protein structural changes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

prostate cancer testIsoPSAliquid biopsycancer detectiondiagnostic testsprotein structural analysiscancer biomarkersproteomicsbiopsy reductionLaboratory Developed TestLDTCLIA certified labCPT codein-vitro diagnostic kitIVD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cleveland Diagnostics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cleveland Diagnostics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 17, 2024
Series DJan 28, 2021
Convertible DebtNov 28, 2017
VC RoundNov 21, 2016
Series AMar 3, 2015

Cleveland Diagnostics Investors

Notable investors and investment history

InvestorRounds
LYFE CapitalSeries D
Symbiotic CapitalVC Round
Novo HoldingsVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    IsoPSA Test for Prostate Cancer gains FDA approval.

  • Mar 1, 2026

    Launched FDA-approved IsoPSA Test for Prostate Cancer nationwide.

Cleveland Diagnostics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cleveland Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cleveland Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCleveland, Ohio
Employee Range98
Year Founded2013
Last FundingJan 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.